EcoDrugPlus

Alcohol Dehydrogenase 5 (Class Iii), Chi Polypeptide

Ensembl ID : ENSTBEG00000015594
Gene Symbol: ADH5
1 Cross references
400 Possible Orthologues:

Aldo-Keto Reductase Family 1 Member B

Ensembl ID : ENSTBEG00000013327
Gene Symbol: AKR1B1
1 Cross references
429 Possible Orthologues:

Amyloid Beta Precursor Protein

Ensembl ID : ENSTBEG00000007745
Gene Symbol: APP
1 Cross references
276 Possible Orthologues:

Androgen Receptor

Ensembl ID : ENSTBEG00000015310
Gene Symbol: AR
1 Cross references
277 Possible Orthologues:

Apelin Receptor

Ensembl ID : ENSTBEG00000008300
Gene Symbol: APLNR
1 Cross references
171 Possible Orthologues:

Aph-1 Homolog A, Gamma-Secretase Subunit

Ensembl ID : ENSTBEG00000003480
Gene Symbol: APH1A
1 Cross references
137 Possible Orthologues:

Aph-1 Homolog B, Gamma-Secretase Subunit

Ensembl ID : ENSTBEG00000009252
Gene Symbol: APH1B
1 Cross references
191 Possible Orthologues:

Apurinic/apyrimidinic Endodeoxyribonuclease 1

Ensembl ID : ENSTBEG00000006405
Gene Symbol: APEX1
1 Cross references
212 Possible Orthologues:

Arachidonate 5-Lipoxygenase Activating Protein

Ensembl ID : ENSTBEG00000013644
Gene Symbol: ALOX5AP
1 Cross references
200 Possible Orthologues:

Arginine Vasopressin Receptor 1a

Ensembl ID : ENSTBEG00000001172
Gene Symbol: AVPR1A
1 Cross references
264 Possible Orthologues:

Arginine Vasopressin Receptor 1b

Ensembl ID : ENSTBEG00000001084
Gene Symbol: AVPR1B
1 Cross references
134 Possible Orthologues:

Aryl Hydrocarbon Receptor

Ensembl ID : ENSTBEG00000007210
Gene Symbol: AHR
1 Cross references
154 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).